Clinical trial
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
NCT00109863 · University of Wisconsin, Madison, Other · Completed
Key facts
| NCT number | NCT00109863 |
|---|---|
| Title | Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma |
| Official title | Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma |
| Lead sponsor | University of Wisconsin, Madison, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | hu14.18-IL2 fusion protein |
| Enrollment | 14 |
| Start date | May 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Feb 1, 2014 |
| First posted | May 4, 2005 |
| Last update posted | Nov 19, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: